Congratulations to our new PhD, Jonathan DeLiberty!
January 16, 2025
Dr. DeLiberty successfully defended his thesis, "Therapeutic Targeting of RAS-Driven Metabolic Dependencies by PIKfyve Inhibition," under the guidance of Drs. Kirsten Bryant and Channing Der.